Sinopharm Hyundai announced on the evening of January 7 that its wholly-owned subsidiary Sinopharm received the “Notice of Approval of the Application for the Marketing of Chemical Ingredients” approved and issued by the State Drug Administration to approve the marketing application for the active ingredient nabupine hydrochloride. Naburpine hydrochloride is a kappa opioid receptor agonist and μ-opioid receptor antagonist, and is a potent central analgesic. The related formulation product, naburpine hydrochloride injection, is mainly used as an adjuvant to induce anesthesia during complex anesthesia, and is also used to relieve moderate to severe pain.

Sinopharm Hyundai announced on the evening of January 7 that its wholly-owned subsidiary Sinopharm received the “Notice of Approval of the Application for the Marketing of Chemical Ingredients” approved and issued by the State Drug Administration to approve the marketing application for the active ingredient nabupine hydrochloride. Naburpine hydrochloride is a kappa opioid receptor agonist and μ-opioid receptor antagonist, and is a potent central analgesic. The related formulation product, naburpine hydrochloride injection, is mainly used as an adjuvant to induce anesthesia during complex anesthesia, and is also used to relieve moderate to severe pain.